Health Top Stories

A major announcement from FDA regarding Peanut Allergy Treatment

Last Wednesday, the officials from Allergenic Products Advisory Committee under the Food and Drugs Association (FDA) took an important decision regarding Peanut Allergy Cases among the kids. They all voted in favour of such allergic treatments, especially among the children. 

 Palforzia is a drug which the US physicians prescribe to those who suffer peanut allergies. It cures such allergies, especially among those who are aged from four to 17 years. Apart from Palforzia, the US doctors also use drugs such as injectable epinephrine which they inject into the patient’s body.

Although the advisory committee has made its approval, the FDA will make its final decision by January 2020. The FDA has followed the lead of the committee most of the times. Once it is approved, it will become the first treatment that the FDA has approved for the peanut allergy cases. 

Aimmune Therapeutics CEO Jayson Dallas has stated that the drugs industry was elated that the FDA advisory committee voted in Palforzia’s favour. It is one of the primary drugs that help to deal with such allergies. This announcement has recognized the importance of this life-saving drug during the peanut allergy’s treatment. 

According to a report, around 3 million USA citizens are allergic to peanuts as well as tree nuts. The American College of Asthma, Allergy and Immunology had conducted a study regarding ‘Peanut Allergy Among American Kids.’ Here, they found out that currently, 2.5% kids of the USA are allergic to peanuts. 

If the allergic kids are exposed to nuts, they start suffering from issues such as shortness of breath, stomach cramping, hives, indigestion, swelling, tightness of breath, low blood pressure, dizziness, fainting, etc. The physicians identify these issues as symptoms of anaphylaxis. It can be fatal in some cases if not treated immediately. Physicians always advise such patients to avoid nuts.

LEAVE A RESPONSE

Your email address will not be published.